Liver Cancer

Ahmed Kaseb, ESMO 2019 – Nivolumab plus ipilimumab in HCC

We joined Ahmed Kaseb (M.D. Anderson Cancer Center) at ESMO 2019 to discuss recent findings from the randomised, open-label, perioperative phase 2 study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma (NCT03222076). Questions 1. What are the major unmet needs in the treatment of resectable hepatocellular carcinoma (HCC)? (00:02) 2. […]

Viktor Grünwald- ECCO 2017

Combination therapy with lenvatinib and everolimus in metastatic renal cell carcinoma – why did this combination succeed where others failed? Katrina Mountfort, Touch Medical Media, Reading, UK, Metastatic renal cell carcinoma (mRCC) is associated with a poor prognosis, with a 5-year survival rate of only 8%.1 Within the last 10 years, a number of potent […]

Lenvatinib in Hepatocellular Carcinoma

European Oncology & Haematology, 2018;14(2):80–1 DOI: https://doi.org/10.17925/EOH.2018.14.2.80

Liver cancer is the second leading cause of cancer-related death, and has limited treatment options and a poor prognosis.1 Mortality owing to liver cancer has increased in the past 20 years, with a reported incidence of 841,080 cases per year.2 Hepatocellular carcinoma (HCC) represents about 90% of primary liver cancer cases.1 Multiple single agent and […]

Updates in the Systemic Treatment of Hepatocellular Carcinoma

Oncology & Hematology Review. 2018;14(2):76–81 DOI: https://doi.org/10.17925/OHR.2018.14.2.76

Liver cancer has contributed to an annual 30,200 deaths in the US so far in 2018.1 An overwhelming majority is due to hepatocellular carcinoma (HCC) in the setting of advanced liver disease.2 While chronic hepatitis C and alcoholic liver disease traditionally have been the most common etiologies of cirrhosis in the US, the prevalence of […]

Tumour Lysis Syndrome in Solid Tumours Associated with Tyrosine Kinase Inhibitors – A Case Illustrated Review

European Oncology & Haematology, 2016;12(1):51–4 DOI: https://doi.org/10.17925/EOH.2016.12.01.51

Tyrosine kinase inhibitors (TKIs) are small anticancer molecules targeting protooncogenic tyrosine kinase signalling pathways.1 TKIs are now therapies used routinely in the treatment of many solid tumours such as gastrointestinal stromal tumour (GIST), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), medullary thyroid cancer, breast cancer and non-small-cell lung carcinoma (Table 1). As opposed to cytotoxic […]

Tumour Lysis Syndrome in Solid Tumours Associated with Tyrosine Kinase Inhibitors – A Case Illustrated Review

European Oncology & Haematology, 2016;12(1):51–4 DOI: https://doi.org/10.17925/EOH.2016.12.01.51

Tyrosine kinase inhibitors (TKIs) are small anticancer molecules targeting protooncogenic tyrosine kinase signalling pathways.1 TKIs are now therapies used routinely in the treatment of many solid tumours such as gastrointestinal stromal tumour (GIST), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), medullary thyroid cancer, breast cancer and non-small-cell lung carcinoma (Table 1). As opposed to cytotoxic […]

Cancer Stem Cells and Cancer Stem Cell Inhibitors in Gastrointestinal Cancers

Oncology & Hematology Review, 2016;12(1):41–6 DOI: https://doi.org/10.17925/OHR.2016.12.01.41

As is the case with most solid tumors, gastrointestinal (GI) tumors are treated in a variety of modalities, which are used singularly or in combination, including surgery, targeted therapies, radiation, and chemotherapy. Survival rates by stage in colon and rectal cancer are given inTable 1. Cancer stem cells (CSCs) are believed to be malignant cells […]

Making Sense of the Advances in the Treatment of Hepatocellular Carcinoma

Oncology & Hematology Review, 2015;11(2):141–2 DOI: https://doi.org/10.17925/OHR.2015.11.02.141

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, with a rising global incidence.1 The majority of HCC occurs in the setting of liver cirrhosis, mainly due to hepatitis C virus (HCV) infection, hepatitis B viral infection, alcohol consumption, or nonalcoholic fatty liver disease. The most important development in HCC is the advent of […]

American Society of Clinical Oncology 2015— Highlights of Non-colorectal Gastrointestinal Cancers

Oncology & Hematology Review, 2015;11(2):137–8 DOI: https://doi.org/10.17925/OHR.2015.11.02.137

The 2015 annual American Society of Clinical Oncology meeting brought refinements rather than major practice changes to the field of noncolorectal gastrointestinal (GI) cancers, with one notable exception and that is for the emerging endorsement of the role of immune therapies in these diseases. Arguably the most important observation from the meeting overall was the […]